Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of Intravenous Fexuprazan in Healthy Participants
NCT06437951Phase 1Not yet recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of fexuprazan in erosive gastroesophageal reflux disease (5 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Pharmacokinetics of Fexuprazan at 72 hours, Pharmacokinetics of metabolite at 72 hours and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
fexuprazan
03
Conditions
erosive gastroesophageal reflux disease
Beyond the preview
Go deeper on NCT06437951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437951.